Blood Test Predicts Onset of Alzheimer's Disease
|
By LabMedica International staff writers Posted on 22 Jul 2014 |
|
Image: The Luminex 200 System for Multiplex Testing (Photo courtesy of the University of Utah).
A combination of 10 proteins could predict whether individuals would progress from mild cognitive impairment to Alzheimer's disease (AD) within a year has been discovered.
Mild cognitive impairment (MCI) which includes problems with day-to-day memory, attention and language can be an early sign of dementia, but it can also be a symptom of stress or anxiety. About 10% of people with MCI go on to develop dementia within a year, however, apart from regular memory tests, there is currently no reliable way to predict who will and will not be among them.
Scientists at King's College London (UK) working with Proteome Sciences plc (Cobham, UK) analyzed blood samples from 1,148 subjects: 476 with AD, 220 with MCI, and 452 elderly controls with no dementia. The team analyzed 26 proteins in the blood samples and found that 16 linked strongly to brain shrinkage in the MCI and Alzheimer's groups. All candidate proteins were measured using xMAP multiplex bead assays incorporated in 7 MILLIPLEX MAP panels run on the Luminex 200 instrument (Luminex; Austin, TX, USA).
In a secondary analysis they discovered that a combination of 10 proteins could predict whether individuals would progress from MCI to Alzheimer's disease within a year with an accuracy of 87%. They found that the proteins transthyretin (TTR), clusterin, cystatin C, alpha-1-acid glycoprotein (A1AcidG), Intercellular Adhesion Molecule 1 (ICAM1), cytochrome c4 precursor (CC4), pigment epithelium-derived factor (PEDF), alpha 1-antitrypsin (A1AT), Chemokine ligand 5 (RANTES), and Apolipoprotein C-III (ApoC3) plus the Apolipoprotein E (APOE) genotype, had the greatest predictive power.
Abdul Hye, PhD, the lead author of the study said, “The study marks the end of many years' work to find which of the thousands of proteins in the blood were clinically relevant. We now have a set of 10 proteins that can predict whether someone with early symptoms of memory loss, or mild cognitive impairment will develop Alzheimer's disease within a year, with a high level of accuracy.” The study was published on July 10, 2014, in the journal Alzheimer's and Dementia.
Related Links:
King's College London
Proteome Sciences plc
Luminex
 (3) (1).png)
Mild cognitive impairment (MCI) which includes problems with day-to-day memory, attention and language can be an early sign of dementia, but it can also be a symptom of stress or anxiety. About 10% of people with MCI go on to develop dementia within a year, however, apart from regular memory tests, there is currently no reliable way to predict who will and will not be among them.
Scientists at King's College London (UK) working with Proteome Sciences plc (Cobham, UK) analyzed blood samples from 1,148 subjects: 476 with AD, 220 with MCI, and 452 elderly controls with no dementia. The team analyzed 26 proteins in the blood samples and found that 16 linked strongly to brain shrinkage in the MCI and Alzheimer's groups. All candidate proteins were measured using xMAP multiplex bead assays incorporated in 7 MILLIPLEX MAP panels run on the Luminex 200 instrument (Luminex; Austin, TX, USA).
In a secondary analysis they discovered that a combination of 10 proteins could predict whether individuals would progress from MCI to Alzheimer's disease within a year with an accuracy of 87%. They found that the proteins transthyretin (TTR), clusterin, cystatin C, alpha-1-acid glycoprotein (A1AcidG), Intercellular Adhesion Molecule 1 (ICAM1), cytochrome c4 precursor (CC4), pigment epithelium-derived factor (PEDF), alpha 1-antitrypsin (A1AT), Chemokine ligand 5 (RANTES), and Apolipoprotein C-III (ApoC3) plus the Apolipoprotein E (APOE) genotype, had the greatest predictive power.
Abdul Hye, PhD, the lead author of the study said, “The study marks the end of many years' work to find which of the thousands of proteins in the blood were clinically relevant. We now have a set of 10 proteins that can predict whether someone with early symptoms of memory loss, or mild cognitive impairment will develop Alzheimer's disease within a year, with a high level of accuracy.” The study was published on July 10, 2014, in the journal Alzheimer's and Dementia.
Related Links:
King's College London
Proteome Sciences plc
Luminex
Gold Member
Hybrid Pipette
SWITCH
Pipette
Accumax Smart Series
Homocysteine Quality Control
Liquichek Homocysteine Control
Latest Clinical Chem. News
- Existing Hospital Analyzers Can Identify Fake Liquid Medical Products
- Rapid Blood Testing Method Aids Safer Decision-Making in Drug-Related Emergencies
- New PSA-Based Prognostic Model Improves Prostate Cancer Risk Assessment
- Extracellular Vesicles Linked to Heart Failure Risk in CKD Patients
- Study Compares Analytical Performance of Quantitative Hepatitis B Surface Antigen Assays
- Blood Test Could Predict and Identify Early Relapses in Myeloma Patients
- Compact Raman Imaging System Detects Subtle Tumor Signals
- Noninvasive Blood-Glucose Monitoring to Replace Finger Pricks for Diabetics
- POC Breath Diagnostic System to Detect Pneumonia-Causing Pathogens
- Online Tool Detects Drug Exposure Directly from Patient Samples
- Chemical Imaging Probe Could Track and Treat Prostate Cancer
- Mismatch Between Two Common Kidney Function Tests Indicates Serious Health Problems
- VOCs Show Promise for Early Multi-Cancer Detection
- Portable Raman Spectroscopy Offers Cost-Effective Kidney Disease Diagnosis at POC
- Gold Nanoparticles to Improve Accuracy of Ovarian Cancer Diagnosis
- Simultaneous Cell Isolation Technology Improves Cancer Diagnostic Accuracy
Channels
Molecular Diagnostics
view channel
New Extraction Kit Enables Consistent, Scalable cfDNA Isolation from Multiple Biofluids
Circulating cell-free DNA (cfDNA) found in plasma, serum, urine, and cerebrospinal fluid is typically present at low concentrations and is often highly fragmented, making efficient recovery challenging... Read more
AI-Powered Liquid Biopsy Classifies Pediatric Brain Tumors with High Accuracy
Liquid biopsies offer a noninvasive way to study cancer by analyzing circulating tumor DNA in body fluids. However, in pediatric brain tumors, the small amount of ctDNA in cerebrospinal fluid has limited... Read more
Hematology
view channel
Rapid Cartridge-Based Test Aims to Expand Access to Hemoglobin Disorder Diagnosis
Sickle cell disease and beta thalassemia are hemoglobin disorders that often require referral to specialized laboratories for definitive diagnosis, delaying results for patients and clinicians.... Read more
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read more
Immunology
view channel
New Biomarker Predicts Chemotherapy Response in Triple-Negative Breast Cancer
Triple-negative breast cancer is an aggressive form of breast cancer in which patients often show widely varying responses to chemotherapy. Predicting who will benefit from treatment remains challenging,... Read more
Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug
Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more
Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment
Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more
Ultrasensitive Liquid Biopsy Demonstrates Efficacy in Predicting Immunotherapy Response
Immunotherapy has transformed cancer treatment, but only a small proportion of patients experience lasting benefit, with response rates often remaining between 10% and 20%. Clinicians currently lack reliable... Read moreMicrobiology
view channel
Rapid Test Promises Faster Answers for Drug-Resistant Infections
Drug-resistant pathogens continue to pose a growing threat in healthcare facilities, where delayed detection can impede outbreak control and increase mortality. Candida auris is notoriously difficult to... Read more
CRISPR-Based Technology Neutralizes Antibiotic-Resistant Bacteria
Antibiotic resistance has accelerated into a global health crisis, with projections estimating more than 10 million deaths per year by 2050 as drug-resistant “superbugs” continue to spread.... Read more
Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease
Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more
Pathology
view channel
Single Sample Classifier Predicts Cancer-Associated Fibroblast Subtypes in Patient Samples
Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest cancers, in part because of its dense tumor microenvironment that influences how tumors grow and respond to treatment.... Read more
New AI-Driven Platform Standardizes Tuberculosis Smear Microscopy Workflow
Sputum smear microscopy remains central to tuberculosis treatment monitoring and follow-up, particularly in high‑burden settings where serial testing is routine. Yet consistent, repeatable bacillary assessment... Read more
AI Tool Uses Blood Biomarkers to Predict Transplant Complications Before Symptoms Appear
Stem cell and bone marrow transplants can be lifesaving, but serious complications may arise months after patients leave the hospital. One of the most dangerous is chronic graft-versus-host disease, in... Read more
Technology
view channel
Blood Test “Clocks” Predict Start of Alzheimer’s Symptoms
More than 7 million Americans live with Alzheimer’s disease, and related health and long-term care costs are projected to reach nearly USD 400 billion in 2025. The disease has no cure, and symptoms often... Read more
AI-Powered Biomarker Predicts Liver Cancer Risk
Liver cancer, or hepatocellular carcinoma, causes more than 800,000 deaths worldwide each year and often goes undetected until late stages. Even after treatment, recurrence rates reach 70% to 80%, contributing... Read more
Robotic Technology Unveiled for Automated Diagnostic Blood Draws
Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more
ADLM Launches First-of-Its-Kind Data Science Program for Laboratory Medicine Professionals
Clinical laboratories generate billions of test results each year, creating a treasure trove of data with the potential to support more personalized testing, improve operational efficiency, and enhance patient care.... Read moreIndustry
view channel
QuidelOrtho Collaborates with Lifotronic to Expand Global Immunoassay Portfolio
QuidelOrtho (San Diego, CA, USA) has entered a long-term strategic supply agreement with Lifotronic Technology (Shenzhen, China) to expand its global immunoassay portfolio and accelerate customer access... Read more
WHX Labs in Dubai spotlights leadership skills shaping next-generation laboratories
WHX Labs in Dubai (formerly Medlab Middle East), held at Dubai World Trade Centre (DWTC) from 10–13 February, brings together international experts to discuss the factors redefining laboratory leadership,... Read more
